A major breakthrough in targeting KRAS came in 2021, when the Food and Drug Administration (FDA) approved sotorasib (AMG-510) for the treatment of KRAS G12C-specific mutations for advanced non-small cell lung cancer (NSCLC) in patients previously treated with at least one systemic therapy. Here, KRAS is linked to non-small cell lung carcinoma.